IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial
Yang, Li1; Cao, Qingjiu1; Shuai, Lan1; Li, Haimei1; Chan, Raymond C. K.2; Wang, Yufeng1
关键词Attention Deficit Hyperactivity Disorder Atomoxetine Executive Function Osmotic Release Oral System-methylphenidate (Oros-mph)
刊名INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
2012-02-01
DOI10.1017/S1461145711001490
15期:1页:15-26
收录类别SCI ; SSCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Neurosciences ; Pharmacology & Pharmacy ; Psychiatry
研究领域[WOS]Neurosciences & Neurology ; Pharmacology & Pharmacy ; Psychiatry
关键词[WOS]DEFICIT-HYPERACTIVITY DISORDER ; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER ; WORKING-MEMORY PERFORMANCE ; ONCE-DAILY ATOMOXETINE ; PREFRONTAL CORTEX ; STIMULANT MEDICATION ; RESPONSE-INHIBITION ; TASK-PERFORMANCE ; STROOP COLOR ; OPEN-LABEL
英文摘要

This study aimed to compare the effects of osmotic release oral system-methylphenidate (OROS-MPH) and atomoxetine (ATX) on executive function in children and adolescents with attention deficit hyperactivity disorder (ADHD) by a randomized controlled trial. Subjects who met DSM-IV ADHD criteria were randomized to receive either OROS-MPH or ATX treatment. The doses were titrated to achieve optimal response and then maintained for 4-6 wk. A battery of executive function tests and the Behavior Rating Inventory of Executive Function (BRIEF) were administered to subjects who completed the dose titration (OROS-MPH, n = 85; ATX, n = 57) at the pre- and post-treatment periods. Forty-six children without ADHD were recruited as controls. Both OROS-MPH and ATX significantly improved scores in the Rey Complex Figure Test (RCFT), digit span, and Stroop color-word task. The scores in RCFT and the reverse digit span were not significantly different from the control group at post-treatment assessment (OROS-MPH = ATX = control, p > 0.05), whereas the word interference time of the Stroop test was still more than that of the control group (OROS-MPH = ATX > control, p > 0.05). OROS-MPH also significantly improved the total correct response in the verbal fluency test to normal level, and the shifting time in the trail-making test to subnormal level. The current findings suggest both OROS-MPH and ATX improved executive function generally in children and adolescents with ADHD, and could return working memory back to normative performance level.

语种英语
WOS记录号WOS:000299498600002
项目编号30800302 ; 200802073 ; 2007BAI17B03 ; CON-I-07-CN-029-B
资助机构National Natural Science Foundation of China ; Chinese Ministry of Health ; Ministry of Science and Technology ; Xian-Janssen Pharmaceutical Ltd ; Xian-Janssen ; Eli Lilly
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56521
专题北京大学精神卫生研究所
北京大学精神卫生研究所_精神科
作者单位1.Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China
2.Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Key Lab Mental Hlth, Beijing 100101, Peoples R China
推荐引用方式
GB/T 7714
Yang, Li,Cao, Qingjiu,Shuai, Lan,et al. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial[J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY,2012,15(1):15-26.
APA Yang, Li,Cao, Qingjiu,Shuai, Lan,Li, Haimei,Chan, Raymond C. K.,&Wang, Yufeng.(2012).Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY,15(1),15-26.
MLA Yang, Li,et al."Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial".INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 15.1(2012):15-26.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Li]的文章
[Cao, Qingjiu]的文章
[Shuai, Lan]的文章
百度学术
百度学术中相似的文章
[Yang, Li]的文章
[Cao, Qingjiu]的文章
[Shuai, Lan]的文章
必应学术
必应学术中相似的文章
[Yang, Li]的文章
[Cao, Qingjiu]的文章
[Shuai, Lan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。